甲状腺激素治疗与亚临床甲减患者生活质量及甲状腺相关症状的关联:系统综述与Meta分析
该系统综述与Meta分析纳入21项随机临床试验共2192例非妊娠亚临床甲减成人,评估甲状腺激素治疗对生活质量和甲状腺相关症状的影响。甲状腺激素治疗使促甲状腺激素均值降至正常参考范围,但与安慰剂相比,在一般生活质量(SMD -0.11,95%CI -0.25至0.03)和甲状腺相关症状(SMD 0.01,95%CI -0.12至0.14)上均无获益。结论不支持对亚临床甲减成人常规使用甲状腺激素治疗。
要点
- 甲状腺激素治疗未改善亚临床甲减成人的一般生活质量。
- 甲状腺激素治疗未改善甲状腺相关症状。
- 不推荐对非妊娠亚临床甲减成人常规使用甲状腺激素。
核心结论
- 在非妊娠亚临床甲减成人中,甲状腺激素治疗与一般生活质量和甲状腺相关症状的改善无关。
- 这些发现不支持对亚临床甲减成人常规使用甲状腺激素治疗。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、EMBASE、ClinicalTrials.gov等数据库至2018年7月4日。
- 纳入21项随机临床试验,共2192例非妊娠亚临床甲减成人,比较甲状腺激素与安慰剂或无治疗。
- 采用随机效应模型,将临床评分差异转换为标准化均数差(SMD),并评估偏倚风险(Cochrane工具)和证据质量(GRADE工具)。
主要发现
- 甲状腺激素治疗使促甲状腺激素均值降至正常参考范围(范围0.5-3.7 mIU/L),而安慰剂组为4.6-14.7 mIU/L。
- 一般生活质量无获益(n=796;SMD -0.11;95%CI -0.25至0.03;I2=66.7%)。
- 甲状腺相关症状无获益(n=858;SMD 0.01;95%CI -0.12至0.14;I2=0.0%)。
- 总体偏倚风险低,GRADE证据质量评为中至高级。
临床怎么用
- 对于非妊娠亚临床甲减成人,不应常规处方甲状腺激素治疗以改善生活质量或甲状腺相关症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The benefit of thyroid hormone therapy for subclinical hypothyroidism is uncertain. New evidence from recent large randomized clinical trials warrants an update of previous meta-analyses. OBJECTIVE: To conduct a meta-analysis of the association of thyroid hormone therapy with quality of life and thyroid-related symptoms in adults with subclinical hypothyroidism. DATA SOURCES: PubMed, EMBASE, ClinicalTrials.gov, Web of Science, Cochrane Library, CENTRAL, Emcare, and Academic Search Premier from inception until July 4, 2018. STUDY SELECTION: Randomized clinical trials that compared thyroid hormone therapy with placebo or no therapy in nonpregnant adults with subclinical hypothyroidism were eligible. Two reviewers independently evaluated eligibility based on titles and abstracts of all retrieved studies. Studies not excluded in this first step were independently assessed for inclusion after full-text evaluation by 2 reviewers. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers extracted data, assessed risk of bias (Cochrane risk-of-bias tool), and evaluated the quality of evidence (GRADE tool). For synthesis, differences in clinical scores were transformed (eg, quality of life) into standardized mean differences (SMDs; positive values indicate benefit of thyroid hormone therapy; 0.2, 0.5, and 0.8 correspond to small, moderate, and large effects, respectively). Random-effects models for meta-analyses were applied. MAIN OUTCOMES AND MEASURES: General quality of life and thyroid-related symptoms after a minimum follow-up of 3 months. RESULTS: Overall, 21 of 3088 initially identified publications met the inclusion criteria, with 2192 adults randomized. After treatment (range, 3-18 months), thyroid hormone therapy was associated with lowering the mean thyrotropin value into the normal reference range compared with placebo (range, 0.5-3.7 mIU/L vs 4.6 to 14.7 mIU/L) but was not associated with benefit regarding general quality of life (n = 796; SMD, -0.11; 95% CI, -0.25 to 0.03; I2=66.7%) or thyroid-related symptoms (n = 858; SMD, 0.01; 95% CI, -0.12 to 0.14; I2=0.0%). Overall, risk of bias was low and the quality of evidence assessed with the GRADE tool was judged moderate to high. CONCLUSIONS AND RELEVANCE: Among nonpregnant adults with subclinical hypothyroidism, the use of thyroid hormone therapy was not associated with improvements in general quality of life or thyroid-related symptoms. These findings do not support the routine use of thyroid hormone therapy in adults with subclinical hypothyroidism.
引用
- Feller M, Snel M, Moutzouri E, et al. Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 30285179. doi:10.1001/jama.2018.13770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。